It is important to note that female patients typically develop HF at an older age and more frequently present with diastolic dysfunction, whereas male patients tend to develop HF with systolic dysfunction [21]. The DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) and EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) studies analyzed the relationship between HF, AF, and the use of SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is heart failure.